ReviewThe lancet. HIV2023
Global HIV control: is the glass half empty or half full?
Review in The lancet. HIV, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Willingness to switch to long-acting regimens among people with HIV: a systematic review and meta-analysis.AIDS (London, England) · 2026Pooled it
- Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis.Frontiers in public health · 2023Pooled it
- A Dyad-Based Intervention to Improve Adherence to Antiretroviral Therapy among People with HIV who Inject Drugs in Kazakhstan: Results of a Randomized Controlled Trial.AIDS and behavior · 2026Trial
- Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.Clinical and molecular hepatology · 2025Trial
- Characterization of a Novel Endolysin Sb1-LysAEJ as a Biocide and Food-contact Surface Disinfectant for the Control of Staphylococcus aureus.Probiotics and antimicrobial proteins · 2026Article
- Preferences for mHealth Features to Support Engagement in the HIV Preexposure Prophylaxis Cascade Among Men Who Have Sex With Men in Peru: Cross-Sectional Online Survey.JMIR public health and surveillance · 2026Article
- [Characterization of immune reconstitution inflammatory syndrome in a Mexican cohort].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Latin America and the Caribbean: Challenges and Opportunities for HIV Treatment and Prevention.Journal of the International AIDS Society · 2026Article
- Clinical outcomes after the implementation of a patient-centered care program applied to newly admitted people with HIV in Mexico City: a retrospective cohort study.AIDS research and therapy · 2026Article
- Exploring multi-level barriers and human-centered solutions to expand methadone for HIV prevention among people who inject drugs in Kyrgyzstan.Journal of substance use and addiction treatment · 2026Article
- Detailed HIV Self-Testing Patterns Derived from Paradata in the mLab App Clinical Trial.AIDS and behavior · 2026Article
- Identifying Implementation Gaps in the HIV Prevention Cascade among Peruvian Men Who Have Sex with Men.AIDS and behavior · 2026Article
- Exploring Perceived Utility of a Clinic-Integrated HIV Prevention App for Men Who Have Sex With Men in Malaysia: A Qualitative Think-Aloud Study.Health science reports · 2026Article
- Global patterns and trends in spontaneous reporting systems: VigiBase, FAERS, VAERS, and JADER.Frontiers in drug safety and regulation · 2026Article
- Probation as a targeted entry point for scaling up opioid agonist therapies in Moldova using a modified screening, brief intervention and referral to treatment strategy.PLOS global public health · 2026Article
- Barriers and facilitators to pre-exposure prophylaxis uptake among high-risk women and men who have sex with men in Georgia: A pre-implementation mixed-methods study using nominal group technique and the COM-B model.PLOS global public health · 2026Article
- Ageing, health system implications, and a changing epidemic: organizational transitions and stigma dynamics in Philippine HIV care.Frontiers in public health · 2026Review
- [Professional practices and commitments in the care of people living with HIV/AIDS].Cadernos de saude publica · 2026Article
- Structural, biophysical, and virological mechanistic characterization of HIV-1 capsid-targeting antivirals.bioRxiv : the preprint server for biology · 2025Article
- Human Immunodeficiency Virus Test Anxiety of Adult Individuals Undergoing Human Immunodeficiency Virus Testing at an Anonymous Testing Center in Türkiye: A Qualitative Study.Florence Nightingale journal of nursing · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 6 countries.
Funding
Abstract
The massive scale-up of HIV treatment and prevention over the past two decades has resulted in important reductions in new infections and mortality globally. Reduction in HIV incidence, however, has been unequal, with worsening epidemics in regions where the reach and scale of HIV control programmes have been insufficient, especially in eastern Europe, central Asia, the Middle East, north Africa, and Latin America where HIV epidemics are concentrated among key populations, including people who inject drugs, men who have sex with men, transgender people, and some minority racial and ethnic groups. The global state of the HIV pandemic highlights disparities in HIV control efforts and provides a roadmap for what should be done, including investment to better implement the effective HIV prevention and treatment tools that are available, but whose adoption and scale-up are not yet sufficient to get us close to an AIDS-free generation. To achieve the full potential of global HIV control, we call for urgent, evidence-informed implementation at scale of our existing and novel HIV prevention and treatment strategies in ways that are better, faster, more efficient, and cost-effective, especially in key populations and regions where the HIV pandemic continues to expand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.